Join our email list to stay up to date on the latest Amyloidosis news.

The U.S. Food and Drug Administration today approved Tegsedi (inotersen), a novel therapy for the treatment of hereditary TTR amyloidosis polyneuropathy.
(more…)

*
*
*








*